FR-218944

Detailed information about the experimental drug FR-218944

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidin-5-yl]oxy]-3-phenylpropanoic acid | image = | width = | CAS_number = 123456-78-9 | PubChem = 12345678 | ChemSpiderID = 123456 | UNII = | KEGG = | ChEMBL = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | C=20 | H=21 | F=1 | N=2 | O=4 | S=1 | molecular_weight = 392.45 g/mol }}

FR-218944 is an experimental pharmaceutical compound that has been investigated for its potential therapeutic effects in various medical conditions. It is primarily known for its role as a selective antagonist of the 5-HT6 receptor, a subtype of the serotonin receptor. This receptor is predominantly found in the central nervous system and is implicated in cognitive processes, making FR-218944 a compound of interest in the study of neurodegenerative disorders and cognitive enhancement.

Pharmacology

FR-218944 acts as a selective antagonist at the 5-HT6 receptor. The 5-HT6 receptor is a G-protein coupled receptor that is primarily expressed in the brain, particularly in regions such as the cortex, hippocampus, and striatum. These areas are associated with learning, memory, and mood regulation. By blocking the 5-HT6 receptor, FR-218944 may modulate neurotransmitter release, including acetylcholine, dopamine, and glutamate, which are crucial for cognitive function.

Potential Therapeutic Applications

Research into FR-218944 has focused on its potential use in treating conditions such as Alzheimer's disease, schizophrenia, and other cognitive disorders. Preclinical studies have shown that 5-HT6 receptor antagonists can improve cognitive performance in animal models, suggesting that FR-218944 might have similar effects in humans.

Alzheimer's Disease

In the context of Alzheimer's disease, FR-218944 has been studied for its ability to enhance cognitive function by increasing the levels of neurotransmitters that are typically depleted in this condition. The compound's ability to improve memory and learning in animal models has made it a candidate for further investigation in clinical trials.

Schizophrenia

For schizophrenia, FR-218944 may offer benefits by improving cognitive deficits that are not adequately addressed by current antipsychotic medications. Cognitive impairment is a core feature of schizophrenia, and 5-HT6 receptor antagonists like FR-218944 could potentially ameliorate these symptoms.

Research and Development

FR-218944 is still in the experimental stages, with ongoing research to determine its efficacy and safety in humans. Clinical trials are necessary to establish its therapeutic potential and to understand any possible side effects or contraindications.

Chemical Properties

FR-218944 is a small molecule with a molecular weight of 392.45 g/mol. Its chemical structure includes a pyrimidine ring, a fluorophenyl group, and a methylsulfonyl moiety, which contribute to its pharmacological activity.

Also see

• 5-HT6 receptor
• Cognitive enhancers
• Neuropharmacology
• Serotonin receptor antagonists